OSCR

Modular <i>in vitro</i> evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma.

Overview

Authors: Jarmila Havelkova1,2,3, Yuriy Petrenko1,2, Anna Stehlikova4, Dana Marekova1, Katerina Peskova1, Michal Pechar4, Martin Studenovsky4, Tomáš Etrych4, Robert Pola4, Pavla Jendelova1
  1. Department of Neuroregeneration, Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czechia
  2. Laboratory of Biomaterials and Tissue Engineering, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
  3. Faculty of Science, Charles University, Prague, Czechia
  4. Department of Biomedical Polymers, Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czechia
Journal: Frontiers in toxicology, volume 8, article 1783704
Dates: received 8 January 2026; accepted 10 April 2026; published online 1 July 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3389/ftox.2026.1783704 · PMID 42453304 · PMCID PMC13367982 · OpenAlex W7166733561
Open access: gold, a free copy (OpenAlex)
Categories: other condition (population), cellular / molecular (subfield)
Methods: Statistics
Keywords: 2D and 3D models, Buparlisib (BKM120), drug delivery, drug evaluation, glioblastoma, nanomedicines, polymer-drug conjugates, spheroids
Topic: Nanoparticle-Based Drug Delivery (Biomaterials, Materials Science), according to OpenAlex
Funding: Ministerstvo Školství, Mládeže a Tělovýchovy (CZ.02, LM2023050, CZ.02.01.01/00/ 22_008/0004562, CZ.02.01); Grantová Agentura České Republiky (GA22-12483S, CZ.02.01.01, CZ.02.01, LM2023050, CZ.02.01.01/00/22_008/0004562)
Citations: not cited yet (Europe PMC); 47 references in the paper

Abstract

Introduction: In this study, we developed a modular in vitro platform that integrates advanced polymer–drug conjugation chemistry with stepwise cytotoxicity screening in both 2D (monolayer) and 3D (spheroids) glioblastoma (GBM) models. Buparlisib was selected as the model therapeutic agent due to its well-characterised mechanism of action, high blood–brain barrier permeability, and relevance to PI3K-targeted therapy.

Methods: Two mechanistically distinct conjugation strategies were explored using N-(2-hydroxypropyl)methacrylamide-based copolymers (pHPMA). The first strategy was based on a redox-sensitive disulphide linkage designed for intracellular glutathione-triggered release, whereas the second used an azide-bearing derivative compatible with strain-promoted azide–alkyne cycloaddition. Drug release was assessed by high-performance liquid chromatography. Biological activity was systematically evaluated in U87MG, U118MG, and T98G cells under 2D conditions using a resazurin-based metabolic activity assay. Subsequently, the more promising disulphide-based formulations were assessed in 3D spheroids by metabolic activity measurements and live-cell monitoring of spheroid growth dynamics.

Results: Free buparlisib showed the strongest inhibitory effect, while its modification and polymer conjugation reduced the apparent activity. Nevertheless, the disulphide-based derivative and polymer conjugate retained concentration-dependent activity, whereas the azide-based polymer conjugate showed minimal effects. Moreover, treatment responses differed between cell lines and between 2D and 3D models.

Discussion: Overall, linker chemistry, cell-line-specific behaviour, and model dimensionality strongly influenced the biological performance of the polymeric buparlisib formulations. The redox-sensitive polymer conjugate therefore represents the more promising strategy for further development.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability statement

The datasets for this study can be found in the Zenodo at [doi.org/10.5281/zenodo.19261011] The repository includes all figures and raw and processed data used in this research.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Funding: added Ministerstvo Školství, Mládeže a Tělovýchovy: CZ.02, LM2023050, CZ.02.01.01/00/ 22_008/0004562, CZ.02.01; Grantová Agentura České Republiky: GA22-12483S, CZ.02.01.01, CZ.02.01, LM2023050, CZ.02.01.01/00/22_008/0004562

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 10 authors, 8 keywords, 44 references.

Cite

This paper

Havelkova, J., Petrenko, Y., Stehlikova, A., Marekova, D., Peskova, K., Pechar, M., Studenovsky, M., Etrych, T., Pola, R., & Jendelova, P. (2026). Modular <i>in vitro</i> evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma. Frontiers in toxicology, 8, 1783704. https://doi.org/10.3389/ftox.2026.1783704

BibTeX

@article{havelkova2026modular,
author = {Havelkova, Jarmila and Petrenko, Yuriy and Stehlikova, Anna and Marekova, Dana and Peskova, Katerina and Pechar, Michal and Studenovsky, Martin and Etrych, Tomáš and Pola, Robert and Jendelova, Pavla},
title = {{Modular \<i\>in vitro\</i\> evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma}},
journal = {Frontiers in toxicology},
year = {2026},
month = jul,
volume = {8},
pages = {1783704},
publisher = {Frontiers Media SA},
issn = {2673-3080},
doi = {10.3389/ftox.2026.1783704},
url = {https://doi.org/10.3389/ftox.2026.1783704},
pmid = {42453304},
pmcid = {PMC13367982}
}

RIS

TY - JOUR
AU - Havelkova, Jarmila
AU - Petrenko, Yuriy
AU - Stehlikova, Anna
AU - Marekova, Dana
AU - Peskova, Katerina
AU - Pechar, Michal
AU - Studenovsky, Martin
AU - Etrych, Tomáš
AU - Pola, Robert
AU - Jendelova, Pavla
TI - Modular <i>in vitro</i> evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma
T2 - Frontiers in toxicology
J2 - Front Toxicol
PY - 2026
DA - 2026/07/01
VL - 8
SP - 1783704
SN - 2673-3080
PB - Frontiers Media SA
DO - 10.3389/ftox.2026.1783704
UR - https://doi.org/10.3389/ftox.2026.1783704
LA - en
ER -

CSL-JSON

{
"id": "10.3389/ftox.2026.1783704",
"type": "article-journal",
"title": "Modular <i>in vitro</i> evaluation of buparlisib-polymeric nanomedicines in 2D and 3D models of glioblastoma",
"container-title": "Frontiers in toxicology",
"author": [
{
"family": "Havelkova",
"given": "Jarmila"
},
{
"family": "Petrenko",
"given": "Yuriy"
},
{
"family": "Stehlikova",
"given": "Anna"
},
{
"family": "Marekova",
"given": "Dana"
},
{
"family": "Peskova",
"given": "Katerina"
},
{
"family": "Pechar",
"given": "Michal"
},
{
"family": "Studenovsky",
"given": "Martin"
},
{
"family": "Etrych",
"given": "Tomáš"
},
{
"family": "Pola",
"given": "Robert"
},
{
"family": "Jendelova",
"given": "Pavla"
}
],
"container-title-short": "Front Toxicol",
"volume": "8",
"page": "1783704",
"DOI": "10.3389/ftox.2026.1783704",
"PMID": "42453304",
"PMCID": "PMC13367982",
"ISSN": "2673-3080",
"publisher": "Frontiers Media SA",
"URL": "https://doi.org/10.3389/ftox.2026.1783704",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
1
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/cells15030219
Reduced LOXL3 Expression Disrupts Microtubule Acetylation and Drives TP53-Dependent Cell Fate in Glioblastoma.
Journal: Cells
In common: other condition, cellular / molecular, 2 references
[2] doi:10.1038/s43856-025-01279-7
Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.
Journal: Communications medicine
In common: other condition, 2 references
[3] doi:10.1186/s13040-024-00411-y [code]
Exploring glioma heterogeneity through omics networks: from gene network discovery to causal insights and patient stratification.
Journal: BioData mining
In common: other condition, 2 references
[4] doi:10.1038/s41467-025-58366-5 [code]
Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression.
Journal: Nature communications
In common: other condition, cellular / molecular, 2 references
[5] doi:10.1038/s41467-023-36707-6 [code]
Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas.
Journal: Nature communications
In common: other condition, cellular / molecular, 2 references
[6] doi:10.1186/s40478-026-02402-y
Overactivation of SHH signaling induces a cascade of dedifferentiation and oncogenesis in a new mouse model for choroid plexus carcinoma.
Journal: Acta neuropathologica communications
In common: other condition, cellular / molecular, 1 reference
[7] doi:10.1016/j.omton.2026.201201
Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.
Journal: Molecular therapy. Oncology
In common: other condition, cellular / molecular, 1 reference
[8] doi:10.1007/s00204-025-04183-0
Oxidative stress-driven disease-associated microglia (DAM)-like polarization in human microglia (HMC3) cells exposed to small-size silver nanoparticles in a transwell co-culture system with neurons (cholinergic differentiated SH-SY5Y) cells in vitro.
Journal: Archives of toxicology
In common: other condition, cellular / molecular, 1 reference
[9] doi:10.1096/fj.202500291rr [code]
Functional 3D Human Neuron-Glioblastoma Model Reveals Cellular Interactions Enabling Drug Safety Assessments.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology
In common: other condition, cellular / molecular, 1 reference
[10] doi:10.1038/s44319-024-00258-8
SOX10 mediates glioblastoma cell-state plasticity.
Journal: EMBO reports
In common: other condition, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.